Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga·04/30/2026 11:46:08
Listen to the news
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
AbbVie (NYSE:ABBV)
- Dividend Yield: 3.39%
- Piper Sandler analyst David Amsellem maintained an Overweight rating and cut the price target from $299 to $294 on April 23, 2026. This analyst has an accuracy rate of 76%
- Canaccord Genuity analyst Gary Nachman initiated coverage on the stock with a Buy rating and a price target of $262 on April 21, 2026. This analyst has an accuracy rate of 59%.
- Recent News: On April 29, AbbVie posted better-than-expected first-quarter earnings.
- Benzinga Pro’s real-time newsfeed alerted to latest ABBV news.
Bristol-Myers Squibb Co (NYSE:BMY)
- Dividend Yield: 4.38%
- B of A Securities analyst Tim Anderson maintained a Buy rating and cut the price target from $68 to $67 on April 9, 2026. This analyst has an accuracy rate of 55%.
- Guggenheim analyst Seamus Fernandez maintained a Buy rating and a price target of $72 on April 8, 2026. This analyst has an accuracy rate of 80%
- Recent News: On April 24, Bristol Myers Squibb-Pfizer Alliance announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company to offer Eliquis on CostPlusDrugs.com.
- Benzinga Pro's real-time newsfeed alerted to latest BMY news
Medtronic PLC (NYSE:MDT)
- Dividend Yield: 3.58%
- UBS analyst Priya Sachdeva maintained a Neutral rating and cut the price target from $104 to $90 on April 22, 2026. This analyst has an accuracy rate of 73%.
- Truist Securities analyst Richard Newitter maintained a Hold rating and cut the price target from $103 to $95 on April 15, 2026. This analyst has an accuracy rate of 64%.
- Recent News: On April 28, Medtronic announced CE Mark for Stealth AXiS™ surgical system.
- Benzinga Pro’s real-time newsfeed alerted to latest MDT news
Photo via Shutterstock
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.